AR069911A1 - Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 - Google Patents
Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155Info
- Publication number
- AR069911A1 AR069911A1 ARP080105584A ARP080105584A AR069911A1 AR 069911 A1 AR069911 A1 AR 069911A1 AR P080105584 A ARP080105584 A AR P080105584A AR P080105584 A ARP080105584 A AR P080105584A AR 069911 A1 AR069911 A1 AR 069911A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- methyl
- monocyclic
- heteroatoms independently
- independently selected
- Prior art date
Links
- 239000003098 androgen Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- -1 chloro (difluoro) methyl Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se relaciona con procesos para la preparacion de tales compuestos, composiciones farmacéuticas que los contienen y su uso en la fabricacion de un medicamento para su uso en la prevencion o tratamiento de afecciones asociadas con el receptor de androgeno. Reivindicacion 1: Un compuesto caracterizado porque es de Formula (1), o una sal farmacéuticamente aceptable del mismo, para su uso como un medicamento donde X3 representa CH o N; representa difluorometil, trifluorometil o cloro(difluoro)metil; Y representa CH, COH o N; R14, de manera idéntica o diferente en cada aparicion, representa hidrogeno o metil; n y p independientemente representan 1 o 2; L1 representa un enlace directo, -(CR9R10)t, -(CR9R10)v-O-(CR9R10)v, -N(R11)-(CH2)q-,-S-(O)- o -S(O)2-; R9 y R10, de manera idéntica o diferente en cada aparicion, representan hidrogeno o metil; q, de manera idéntica o diferente en cada aparicion, representa 0, 1, 2 o 3; t representa 1, 2 o 3; v, de manera idéntica o diferente en cada aparicion, representa 0, 1 o 2; J representa: aril; un anillo carbocíclico de 3 a 6 miembros monocíclico totalmente saturado; un anillo heterocíclico de 4, 5, 6 o 7 miembros monocíclico el cual comprende 1, 2, 3 o 4 heteroátomos independientemente seleccionados de O, N o S; un anillo heteroaril de 5 o 6 miembros monocíclico que comprende 1, 2, 3 o 4 heteroátomos independientemente seleccionados de O, N o S; o un sistema de anillos heteroaril de 9 o 10 miembros bicíclico que comprende 1, 2, 3, 4 o 5 heteroátomos independientemente seleccionados de O, N o S; L3 representa un enlace directo, -(CR9R10)t-, C(O)N(R11)-(CH2)q-, C(O)N(R11)-(CH2)q-S(O)2-, -NR11C (O)-(CH2)q, -C(O)(CH2)q-, -O-(CH2)q-, -O-(CH2)q-NR11-(CH2)q-, -O-(CH2)q-C(O)NR11-(CH2)q-, -S-, -S(O)- o -S(O)2-; R11 representa hidrogeno o metil; R12 representa: halo, C1-6alquil, C2-6alquenil, C2-6alquinil, carboxi, C1-6alcoxi, ciano, oxo, fluoroC1-6alquil, hidroxi, amino, N-C1-4alquiIamino o N,N-di-C1-4aIquilamino; aril, donde el anillo aril está opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados de R13; un anillo heteroaril de 5 o 6 miembros monocíclico el cual comprende 1, 2, 3 o 4 heteroátomos independientemente seleccionados de O, N o S y donde el anillo heteroaril está opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados de R13; o un anillo heterocíclico de 4, 5, 6 o 7 miembros monocíclico el cual comprende 1, 2, 3 o 4 heteroátomos independientemente seleccionados de O, N o S y donde el anillo heterocíclico está opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados de R13; R13 representa amino, halo, C1-6alquil, C2-6alquenil, C2-6alquinil, C1-6alcoxi, C2-6alcanoil, C1-6alcoxiC1-6alquil, carboxi, ciano, oxo, fluoroC1-6alquiI, hidroxi, hidroxiC1-6alquil, C1-6alquilsulfanil, C1-6alquilsulfinil, C1-6alquilsulfonil, N-C1-4alquilamino, N,N-di-C1-4alquilamino o -C(O)NR14R15 donde R14 y R15 independientemente representan hidrogeno o metil; y r representa 0, 1, 2 o 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1575507P | 2007-12-21 | 2007-12-21 | |
| US9609008P | 2008-09-11 | 2008-09-11 | |
| US10780408P | 2008-10-23 | 2008-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069911A1 true AR069911A1 (es) | 2010-03-03 |
Family
ID=40428336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105584A AR069911A1 (es) | 2007-12-21 | 2008-12-19 | Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8003649B2 (es) |
| EP (1) | EP2235010A1 (es) |
| JP (1) | JP2011507824A (es) |
| KR (1) | KR20100099742A (es) |
| CN (1) | CN101952286A (es) |
| AR (1) | AR069911A1 (es) |
| AU (1) | AU2008339572B2 (es) |
| BR (1) | BRPI0821676A2 (es) |
| CA (1) | CA2709514A1 (es) |
| CL (1) | CL2008003846A1 (es) |
| CO (1) | CO6331441A2 (es) |
| CR (1) | CR11524A (es) |
| DO (1) | DOP2010000195A (es) |
| EA (1) | EA017144B1 (es) |
| EC (1) | ECSP10010291A (es) |
| IL (1) | IL206284A0 (es) |
| NI (1) | NI201000110A (es) |
| NZ (1) | NZ586913A (es) |
| PE (1) | PE20091157A1 (es) |
| TW (1) | TW200927121A (es) |
| UY (1) | UY31559A1 (es) |
| WO (1) | WO2009081197A1 (es) |
| ZA (1) | ZA201004227B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008013791A2 (en) * | 2006-07-24 | 2008-01-31 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| US8188083B2 (en) * | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2009105214A2 (en) | 2008-02-22 | 2009-08-27 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| MX2011006682A (es) | 2008-12-22 | 2011-07-13 | Merck Patent Gmbh | Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion. |
| SG172986A1 (en) | 2009-02-10 | 2011-08-29 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| US20100292222A1 (en) * | 2009-05-11 | 2010-11-18 | Astrazeneca Ab | Chemical compounds 751 |
| US8450374B2 (en) * | 2009-06-29 | 2013-05-28 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| PT2491038T (pt) | 2009-10-23 | 2016-07-14 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011082271A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| CA2799183A1 (en) | 2010-05-12 | 2011-11-17 | Radius Health, Inc. | Therapeutic regimens |
| MX2012013130A (es) * | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US9422290B2 (en) * | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| US9765075B2 (en) | 2013-05-13 | 2017-09-19 | Glaxosmithkline Llc | Substituted bridged urea analogs as sirtuin modulators |
| BR112015030248A2 (pt) * | 2013-06-10 | 2017-07-25 | Astellas Pharma Inc | composto de amida heterocíclica aromática contendo nitrogênio bicíclico |
| NO2719005T3 (es) * | 2014-07-28 | 2018-01-20 | ||
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| WO2016161125A1 (en) * | 2015-03-31 | 2016-10-06 | University Of Vermont And State Agricultural College | Methods for treating cryptosporidiosis using triazolopyridazines |
| KR102559922B1 (ko) | 2016-03-10 | 2023-07-25 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| KR102269305B1 (ko) | 2016-06-13 | 2021-06-25 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| ES2913470T3 (es) | 2016-06-22 | 2022-06-02 | Ellipses Pharma Ltd | Métodos de tratamiento de cáncer de mama AR+ |
| KR20220119520A (ko) | 2017-03-28 | 2022-08-29 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
| EP3661934B1 (en) * | 2017-08-04 | 2022-06-01 | Bristol-Myers Squibb Company | [1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds |
| GB201716871D0 (en) * | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| GB201806663D0 (en) * | 2018-04-24 | 2018-06-06 | Avexxin As | 2-Oxothiazole compositions for treatment of fibrotic disease |
| JP7398452B2 (ja) | 2018-11-14 | 2023-12-14 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物を作製する改良された合成方法 |
| US12521386B2 (en) * | 2018-12-11 | 2026-01-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof |
| CN109942574B (zh) * | 2019-01-11 | 2022-04-01 | 成都阿奇生物医药科技有限公司 | 天奇替尼及其制备方法和用途 |
| BR112021011762A2 (pt) | 2019-01-15 | 2021-11-03 | Gilead Sciences Inc | Compostos para modulação de fxr (nr1h4) |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| KR102725082B1 (ko) | 2019-02-19 | 2024-11-04 | 길리애드 사이언시즈, 인코포레이티드 | Fxr 효능제의 고체 형태 |
| EP4023649A1 (en) * | 2020-12-30 | 2022-07-06 | Industrial Technology Research Institute | Androgen receptor binding bifunctional molecules |
| WO2024189472A1 (en) | 2023-03-14 | 2024-09-19 | Janssen Pharmaceutica Nv | Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators |
| WO2025099660A1 (en) * | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300151T3 (es) | 1998-09-22 | 2008-06-01 | Astellas Pharma Inc. | Derivados de cianofenilo. |
| US6184249B1 (en) | 1998-12-18 | 2001-02-06 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| ATE481969T1 (de) * | 2004-10-01 | 2010-10-15 | Merck Sharp & Dohme | Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes |
| WO2008109104A1 (en) * | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
-
2008
- 2008-12-18 CN CN200880127073XA patent/CN101952286A/zh active Pending
- 2008-12-18 KR KR1020107016410A patent/KR20100099742A/ko not_active Withdrawn
- 2008-12-18 JP JP2010538919A patent/JP2011507824A/ja active Pending
- 2008-12-18 PE PE2008002119A patent/PE20091157A1/es not_active Application Discontinuation
- 2008-12-18 AU AU2008339572A patent/AU2008339572B2/en not_active Ceased
- 2008-12-18 EP EP08863828A patent/EP2235010A1/en not_active Withdrawn
- 2008-12-18 BR BRPI0821676-2A patent/BRPI0821676A2/pt not_active IP Right Cessation
- 2008-12-18 NZ NZ586913A patent/NZ586913A/en not_active IP Right Cessation
- 2008-12-18 EA EA201000946A patent/EA017144B1/ru not_active IP Right Cessation
- 2008-12-18 CA CA2709514A patent/CA2709514A1/en not_active Abandoned
- 2008-12-18 US US12/338,405 patent/US8003649B2/en not_active Expired - Fee Related
- 2008-12-18 WO PCT/GB2008/051206 patent/WO2009081197A1/en not_active Ceased
- 2008-12-19 CL CL2008003846A patent/CL2008003846A1/es unknown
- 2008-12-19 TW TW097149898A patent/TW200927121A/zh unknown
- 2008-12-19 UY UY31559A patent/UY31559A1/es not_active Application Discontinuation
- 2008-12-19 AR ARP080105584A patent/AR069911A1/es not_active Application Discontinuation
-
2010
- 2010-06-10 IL IL206284A patent/IL206284A0/en unknown
- 2010-06-14 ZA ZA2010/04227A patent/ZA201004227B/en unknown
- 2010-06-21 EC EC2010010291A patent/ECSP10010291A/es unknown
- 2010-06-21 CR CR11524A patent/CR11524A/es not_active Application Discontinuation
- 2010-06-21 CO CO10074454A patent/CO6331441A2/es not_active Application Discontinuation
- 2010-06-21 DO DO2010000195A patent/DOP2010000195A/es unknown
- 2010-06-21 NI NI201000110A patent/NI201000110A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2010000195A (es) | 2010-08-31 |
| EP2235010A1 (en) | 2010-10-06 |
| ECSP10010291A (es) | 2010-07-30 |
| AU2008339572B2 (en) | 2012-05-10 |
| NI201000110A (es) | 2012-05-14 |
| CO6331441A2 (es) | 2011-10-20 |
| NZ586913A (en) | 2012-06-29 |
| US20100016279A1 (en) | 2010-01-21 |
| IL206284A0 (en) | 2010-12-30 |
| BRPI0821676A2 (pt) | 2015-06-16 |
| KR20100099742A (ko) | 2010-09-13 |
| PE20091157A1 (es) | 2009-09-03 |
| ZA201004227B (en) | 2011-10-26 |
| WO2009081197A1 (en) | 2009-07-02 |
| US8003649B2 (en) | 2011-08-23 |
| UY31559A1 (es) | 2009-08-03 |
| CN101952286A (zh) | 2011-01-19 |
| EA201000946A1 (ru) | 2010-12-30 |
| EA017144B1 (ru) | 2012-10-30 |
| CR11524A (es) | 2010-08-05 |
| JP2011507824A (ja) | 2011-03-10 |
| CA2709514A1 (en) | 2009-07-02 |
| AU2008339572A1 (en) | 2009-07-02 |
| TW200927121A (en) | 2009-07-01 |
| CL2008003846A1 (es) | 2010-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069911A1 (es) | Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| ES2648037T3 (es) | Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral | |
| WO2019213005A1 (en) | Small molecule degraders of polybromo-1 (pbrm1) | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| ES2939260T3 (es) | Derivado de gamma-aminoácido tricíclico condensado, método de preparación del mismo y uso médico del mismo | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| HRP20191857T1 (hr) | Inhibitori replikacije virusa | |
| AR030306A1 (es) | Derivados de piperazina, un procedimiento para su preparacion, composiciones farmaceuticas, un metodo para su fabricacion y el uso de dichos derivados para la fabricacion de un medicamento | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| AU2015222805A1 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| US12162861B2 (en) | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
| FI3632443T3 (fi) | Kasvainkasvua ehkäisevän vaikutuksen tehostaja, jossa käytetään bifenyyliyhdistettä | |
| AR038887A1 (es) | Amidas heterociclicas | |
| MX2023001725A (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos. | |
| AU2014335859B2 (en) | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction | |
| ES2910455T3 (es) | Compuestos de tiazolidinona y su uso en el tratamiento de condiciones psiquiátricas o trastornos neurológicos e inflamación, en particular neuroinflamación | |
| MX2023011518A (es) | Compuestos heterocíclicos novedosos y sus usos. | |
| RU2506079C1 (ru) | 2-(3-ГИДРОКСИ-4-МЕТОКСИФЕНИЛ)-4,7-ДИМЕТИЛ-3,4,4а,5,8,8а-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛ В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |